These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

707 related articles for article (PubMed ID: 25887482)

  • 1. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
    Jézéquel P; Loussouarn D; Guérin-Charbonnel C; Campion L; Vanier A; Gouraud W; Lasla H; Guette C; Valo I; Verrièle V; Campone M
    Breast Cancer Res; 2015 Mar; 17():43. PubMed ID: 25887482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications.
    Jézéquel P; Kerdraon O; Hondermarck H; Guérin-Charbonnel C; Lasla H; Gouraud W; Canon JL; Gombos A; Dalenc F; Delaloge S; Lemonnier J; Loussouarn D; Verrièle V; Campone M
    Breast Cancer Res; 2019 May; 21(1):65. PubMed ID: 31101122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. M1 Polarization Markers Are Upregulated in Basal-Like Breast Cancer Molecular Subtype and Associated With Favorable Patient Outcome.
    Hachim MY; Hachim IY; Talaat IM; Yakout NM; Hamoudi R
    Front Immunol; 2020; 11():560074. PubMed ID: 33304345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
    Amara D; Wolf DM; van 't Veer L; Esserman L; Campbell M; Yau C
    Breast Cancer Res Treat; 2017 Jan; 161(1):41-50. PubMed ID: 27815749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. iTRAQ-Based Quantitative Proteomic Analysis Strengthens Transcriptomic Subtyping of Triple-Negative Breast Cancer Tumors.
    Jézéquel P; Guette C; Lasla H; Gouraud W; Boissard A; Guérin-Charbonnel C; Campone M
    Proteomics; 2019 Nov; 19(21-22):e1800484. PubMed ID: 30951236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers.
    Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
    Clin Breast Cancer; 2018 Oct; 18(5):e1123-e1132. PubMed ID: 29754847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses.
    Prado-Vázquez G; Gámez-Pozo A; Trilla-Fuertes L; Arevalillo JM; Zapater-Moros A; Ferrer-Gómez M; Díaz-Almirón M; López-Vacas R; Navarro H; Maín P; Feliú J; Zamora P; Espinosa E; Fresno Vara JÁ
    Sci Rep; 2019 Feb; 9(1):1538. PubMed ID: 30733547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes.
    Lee HJ; Lee JJ; Song IH; Park IA; Kang J; Yu JH; Ahn JH; Gong G
    Breast Cancer Res Treat; 2015 Jun; 151(3):619-27. PubMed ID: 26006068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.
    Liu YR; Jiang YZ; Xu XE; Yu KD; Jin X; Hu X; Zuo WJ; Hao S; Wu J; Liu GY; Di GH; Li DQ; He XH; Hu WG; Shao ZM
    Breast Cancer Res; 2016 Mar; 18(1):33. PubMed ID: 26975198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype.
    Jézéquel P; Lasla H; Gouraud W; Basseville A; Michel B; Frenel JS; Juin PP; Ben Azzouz F; Campone M
    Breast Cancer; 2024 Sep; 31(5):825-840. PubMed ID: 38777987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
    Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
    Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Notch pathway down-regulation with Triple Negative/Basal-like breast carcinomas and high tumor-infiltrating FOXP3+ Tregs.
    Ortiz-Martínez F; Gutiérrez-Aviñó FJ; Sanmartín E; Pomares-Navarro E; Villalba-Riquelme C; García-Martínez A; Lerma E; Peiró G
    Exp Mol Pathol; 2016 Jun; 100(3):460-8. PubMed ID: 27118257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer.
    Liu YR; Jiang YZ; Xu XE; Hu X; Yu KD; Shao ZM
    Clin Cancer Res; 2016 Apr; 22(7):1653-62. PubMed ID: 26813360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-negative Breast Cancer-A Single Centre Prospective Observational Study.
    Constantinou C; Papadopoulos S; Karyda E; Alexopoulos A; Agnanti N; Batistatou A; Harisis H
    In Vivo; 2018; 32(2):303-311. PubMed ID: 29475913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
    Roll JD; Rivenbark AG; Sandhu R; Parker JS; Jones WD; Carey LA; Livasy CA; Coleman WB
    Exp Mol Pathol; 2013 Dec; 95(3):276-87. PubMed ID: 24045095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
    De Brot M; Rocha RM; Soares FA; Gobbi H
    Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miRNA-135b Contributes to
    Uva P; Cossu-Rocca P; Loi F; Pira G; Murgia L; Orrù S; Floris M; Muroni MR; Sanges F; Carru C; Angius A; De Miglio MR
    Int J Med Sci; 2018; 15(6):536-548. PubMed ID: 29725243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
    Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
    Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.
    Gasparini P; Fassan M; Cascione L; Guler G; Balci S; Irkkan C; Paisie C; Lovat F; Morrison C; Zhang J; Scarpa A; Croce CM; Shapiro CL; Huebner K
    PLoS One; 2014; 9(2):e88525. PubMed ID: 24505496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk.
    Yau C; Sninsky J; Kwok S; Wang A; Degnim A; Ingle JN; Gillett C; Tutt A; Waldman F; Moore D; Esserman L; Benz CC
    Breast Cancer Res; 2013; 15(5):R103. PubMed ID: 24172169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.